Business Context and Reporting Period
This Form 8-K filing by DarioHealth Corp. (an emerging growth company) reports corporate governance changes effective June 29, 2018, and July 5, 2018. The report was filed on July 6, 2018.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignations: Malcolm Hoenlein resigned as a member of the Board of Directors on June 29, 2018. Erez Raphael resigned as Chairman of the Board on July 5, 2018, though he remains a director and Chief Executive Officer.
- Appointments: Yoav Shaked was appointed as a director and Chairman of the Board on July 5, 2018, to fill the vacancy left by Mr. Hoenlein.
- Committee Assignments: Mr. Shaked was appointed to the Audit, Compensation, and Nomination Committees.
Outlook, Risks, and Management Commentary
Management Commentary: The Board appointed Mr. Shaked due to his extensive experience in biotechnology and venture capital, including his role as a partner at Sequoia Capital and his history of founding and leading medical device companies.
Risks and Contingencies: The filing explicitly states that Mr. Hoenlein's resignation was voluntary and not the result of any disagreement with the Company regarding operations, policies, or practices. No other risks or contingencies are disclosed in this document.
Key Facts for Investor Verification
- Confirm the effective dates of the Board composition changes (June 29 and July 5, 2018).
- Verify that Erez Raphael continues to serve as CEO despite stepping down as Chairman.
- Review Mr. Shaked's background in venture capital and biotechnology to assess the strategic rationale for his appointment.
- Note that no financial data is included in this specific filing; refer to recent 10-K or 10-Q filings for financial metrics.